Clinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment

2020 ◽  
Vol 50 (10) ◽  
pp. 1118-1127
Author(s):  
Yuki Tahata ◽  
Ryotaro Sakamori ◽  
Ayako Urabe ◽  
Ryoko Yamada ◽  
Kazuyoshi Ohkawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Clinical Outcomes ◽  
Interferon Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

A nurse-led, telehealth-driven hepatitis C management initiative in regional Victoria: Cascade of care from referral to cure

2021 ◽  
pp. 1357633X2110241
Author(s):  
Beverly Rodrigues ◽  
Nola Parsons ◽  
James Haridy ◽  
Bloom Stephen ◽  
Caroline Day ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Clinical Outcomes ◽  
World Health ◽  
Clinical Nurse ◽  
Direct Acting Antiviral ◽  
Nurse Consultant ◽  
Direct Acting ◽  
Virus Management

Introduction Elimination of hepatitis C virus stands as an unresolved World Health Organization target, and is associated with complications including cirrhosis and hepatocellular carcinoma. Hepatitis C virus management has been revolutionised following the widespread availability of direct-acting antiviral agents in Australia since 2016; however, large proportions of the population remain untreated. Telehealth-based service delivery is an accessible and effective alternative, and we aimed to assess qualitative and clinical outcomes in a clinical nurse consultant-led regional telehealth model. Methods A prospective cohort analysis of all patients referred to a Victorian regional hospital’s hepatitis C virus telehealth clinic between 1 April 2017 and 10 June 2020 was conducted. Data were collated from outpatient and electronic medical records. Results Fifty-five out of 71 referred patients were booked, with 44 patients (80%) attending at least one appointment. A history of alcohol use disorder and psychiatric comorbidity was seen in 25 (54%) and 24 (52%) patients, respectively. Twenty-one out of 24 (88%) eligible patients had direct-acting antiviral agent treatment and 14 out of 21 (67%) successfully completed the treatment. An average of 46.5 km, 54.6 min and $AUD30.70 was saved per patient for each visit. Observed benefits included: increased medical engagement, adherence to and completion of HCV treatment and cirrhosis monitoring. Telehealth-driven hepatocellular carcinoma surveillance was successful in the cirrhotic subgroup. Conclusion Clinical nurse consultant-led hepatitis C virus management via telehealth allows access to marginalised regional populations. Clinical outcomes were comparable to other cohorts with additional cost-benefit, efficiency gains and carbon footprint reduction amongst a previously unreported regional Victorian hepatitis C virus population.

scholarly journals Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases

2021 ◽  
Author(s):  
R. Tapia-Sosa ◽  
F. Hernández-Cabral ◽  
A. Gabutti ◽  
V.M. Páez-Zayas ◽  
I. García-Juárez
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 210
Author(s):  
Martynas Ridziauskas ◽  
Birutė Zablockienė ◽  
Ligita Jančorienė ◽  
Artūras Samuilis ◽  
Rolandas Zablockis ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Liver Stiffness ◽  
Direct Acting Antiviral ◽  
End Of Treatment ◽  
Increased Risk ◽  
Patients With Diabetes ◽  
Direct Acting

Background and Objectives: Chronic hepatitis C virus infection affects about 71 million people worldwide. It is one of the most common chronic liver conditions associated with an increased risk of developing liver cirrhosis and cancer. The aim of this study was to evaluate changes in liver fibrosis and the risk of developing hepatocellular carcinoma after direct-acting antiviral drug therapy, and to assess factors, linked with these outcomes. Materials and Methods: 70 chronic hepatitis C patients were evaluated for factors linked to increased risk of de novo liver cancer and ≥ 20% decrease of ultrasound transient elastography values 12 weeks after the end of treatment. Results: The primary outcome was an improvement of liver stiffness at the end of treatment (p = 0.004), except for patients with diabetes mellitus type 2 (p = 0.49). Logistic regression analysis revealed factors associated with ≥ 20% decrease of liver stiffness values: lower degree of steatosis in liver tissue biopsy (p = 0.053); no history of interferon-based therapy (p = 0.045); elevated liver enzymes (p = 0.023–0.036); higher baseline liver stiffness value (p = 0.045) and absence of splenomegaly (p = 0.035). Hepatocellular carcinoma developed in 4 (5.7%) patients, all with high alpha-fetoprotein values (p = 0.0043) and hypoechoic liver mass (p = 0.0001), three of these patients had diabetes mellitus type 2. Conclusions: Liver stiffness decrease was significant as early as 12 weeks after the end of treatment. Patients with diabetes and advanced liver disease are at higher risk of developing non-regressive fibrosis and hepatocellular carcinoma even after successful treatment.

Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy

2018 ◽  
Vol 26 (2) ◽  
pp. 231-235 ◽  
Author(s):  
Arash Vaziri ◽  
Alexander Gimson ◽  
Kosh Agarwal ◽  
Mark Aldersley ◽  
Andrew Bathgate ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
United Kingdom ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Antiviral Therapy ◽  
Direct Acting Antiviral ◽  
The United Kingdom ◽  
Direct Acting

scholarly journals Simple Stratification of Hepatocellular Carcinoma Surveillance after Direct-acting Antiviral Therapy for Chronic Hepatitis C

2020 ◽  
Vol 32 (2) ◽  
pp. 125-133
Author(s):  
Tianpeng WANG ◽  
Masashi SAKAKI ◽  
Yuki ICHIKAWA ◽  
Yumi OTOYAMA ◽  
Yoko NAKAJIMA ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Direct Acting Antiviral ◽  
Hepatocellular Carcinoma Surveillance ◽  
Direct Acting

Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma

2019 ◽  
Vol 51 (1) ◽  
pp. 34-52 ◽  
Author(s):  
Sichan He ◽  
Ian Lockart ◽  
Maryam Alavi ◽  
Mark Danta ◽  
Behzad Hajarizadeh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

The dynamic effect of direct‐acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C

2019 ◽  
Vol 26 (12) ◽  
pp. 1489-1492 ◽  
Author(s):  
Clovis Lusivika‐Nzinga ◽  
Hélène Fontaine ◽  
Céline Dorival ◽  
Mélanie Simony ◽  
Stanislas Pol ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Dynamic Effect ◽  
Direct Acting Antiviral ◽  
Direct Acting

Clinical Outcomes of Sofosbuvir-Based Direct-Acting Antiviral Therapy in Kidney Transplant Recipients Infected with Hepatitis C Virus

2018 ◽  
Vol 102 ◽  
pp. S229
Author(s):  
Mohamad Alkadi ◽  
Essa Abuhelaiqa ◽  
Omar Fituri ◽  
Moataz Derbala ◽  
Mona Jarman ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Clinical Outcomes ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document